Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.

Trends in immunology·2026

Same author

Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes.

Immunobiology·2026

Same author

Insights into ctDNA assessment to detect minimal residual disease (MRD) in localized colorectal cancer.

Scientific reports·2026

Same author

Editorial: Current insights in melanoma immunology, immune escape and immunotherapy advances.

Frontiers in immunology·2026

Same author

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma.

Cell reports. Medicine·2026

Same author

Effects and mechanisms of three regulators in enhancing quality and removing toxins and pesticides during wheat straw vermicomposting.

Bioresource technology·2026

Same journal

Advances in nano biomaterials for biomedical engineering.

International review of cell and molecular biology·2026

Same journal

MRI acute/sub-acute ischemic stroke segmentation with deep learning: A comprehensive review.

International review of cell and molecular biology·2026

Same journal

Bioink-based 3D bioprinting: Paving the path for regenerative medicine.

International review of cell and molecular biology·2026

Same journal

Advances in ferroptosis research and applications.

International review of cell and molecular biology·2026

Same journal

Neurodiagnostic: Advances in diagnostic tools.

International review of cell and molecular biology·2026

Same journal

Recent advances in nanomedicine as drug delivery system.

International review of cell and molecular biology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 22, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Engineering interleukin-10 for therapeutic applications.

Yufei Zheng¹, Román García-Fuentes¹, Aline Risson¹

¹Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.

International Review of Cell and Molecular Biology

|May 20, 2026

Summary

This summary is machine-generated.

Engineered Interleukin-10 (IL-10) therapies overcome limitations like short half-life, enhancing anti-inflammatory potential. Bioengineering strategies improve stability, targeting, and efficacy for treating diseases like cancer and autoimmunity.

Keywords:

Cytokine IL-10 Immunotherapy Pleiotropism Tumor microenvironment

More Related Videos

Development of Recombinant Proteins to Treat Chronic Pain

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Related Experiment Videos

Last Updated: May 22, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Development of Recombinant Proteins to Treat Chronic Pain

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Area of Science:

Biotechnology
Immunology
Protein Engineering

Background:

Interleukin-10 (IL-10) is a crucial cytokine for immune regulation, possessing strong anti-inflammatory properties.
Therapeutic application of IL-10 is hindered by its short half-life and pleiotropic effects.

Purpose of the Study:

To review bioengineering strategies for modifying IL-10 to enhance its therapeutic potential.
To examine advancements in IL-10 stability, activity tailoring, and targeted delivery.

Main Methods:

Fusion proteins (cytokine/cytokine, IL-10-Fc, bispecific constructs).
Encapsulation systems (nanoparticles, hydrogels).
Protein engineering for receptor engagement modulation.
Targeted delivery (antibody-mediated, intestinal-specific).
Receptor-based fusion proteins (immunoadhesins).

Main Results:

Reviewed strategies demonstrate improved IL-10 pharmacokinetics, pharmacodynamics, and efficacy in preclinical models.
Evaluated approaches include cancer, autoimmunity, colitis, fibrosis, and transplantation models.
Discussed advantages and limitations such as immunogenicity, delivery efficiency, and scalability.

Conclusions:

Bioengineering is unlocking IL-10's therapeutic potential by overcoming previous limitations.
These advancements pave the way for next-generation cytokine immunotherapies.